Jun 10, 2021
|
Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
|
|
Jun 09, 2021
|
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
|
|
Jun 09, 2021
|
CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
|
|
May 10, 2021
|
Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13
|
|
Apr 29, 2021
|
Vertex Reports First-Quarter 2021 Financial Results
|
|
Apr 28, 2021
|
Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR gene
|
|
Apr 26, 2021
|
Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development
|
|
Apr 22, 2021
|
Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
|
|
Apr 19, 2021
|
Vertex to Announce First-Quarter 2021 Financial Results on April 29
|
|
Mar 26, 2021
|
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation
|
|
Mar 24, 2021
|
Vertex Receives Australian TGA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation
|
|
Mar 10, 2021
|
Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes
|
|
Feb 24, 2021
|
Vertex to Present at the Cowen Health Care Conference on March 2
|
|
Feb 01, 2021
|
Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
|
|
Jan 28, 2021
|
Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)
|
|
Jan 26, 2021
|
Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
|
|
Jan 22, 2021
|
Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
|
|
Jan 07, 2021
|
Vertex to Present at the J.P. Morgan Healthcare Conference on January 11
|
|
Dec 28, 2020
|
Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada
|
|
Dec 22, 2020
|
Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases
|
|